2-Aminoheptane - CAS 123-82-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
2-Aminoheptane
Catalog Number:
123-82-0
Synonyms:
(RS)-2-aminoheptane;1-Methylhexanamine;1-Methylhexylamin;1-methyl-hexylamin;2-Aminoheptan;2-Heptanamine
CAS Number:
123-82-0
Description:
2-Aminoheptane, a fatty Amine compound, is commonly used in proteomics research and could also be used to product some A3 adenosine receptor antagonists.
Molecular Weight:
115.22
Molecular Formula:
C7H17N
Quantity:
Grams-Kilos
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CCCCCC(C)N
InChI:
InChI=1S/C7H17N/c1-3-4-5-6-7(2)8/h7H,3-6,8H2,1-2H3
InChIKey:
VSRBKQFNFZQRBM-UHFFFAOYSA-N
Targets:
Others
Chemical Structure
CAS 123-82-0 2-Aminoheptane

Related Products


CAS 16208-51-8 Dimesna

Dimesna
(CAS: 16208-51-8)

Dimesna is a synthetic derivative of dithio-ethane sulfonate with uroprotective properties. In the kidney, dimesna undergoes reduction to the free thiol compoun...

CAS 1077-28-7 DL-ThioCtic acid

DL-ThioCtic acid
(CAS: 1077-28-7)

DL-α-Lipoic acid is an non-specific free radical scavenger and has anti-oxidant properties. It could be used as a fat-metabolism stimulator.

CGP-15720 hydrochloride
(CAS: 76692-12-1)

CGP-15720 is a antitumor agent

CAS 6537-80-0 Chicoric acid

Chicoric acid
(CAS: 6537-80-0)

Chicoric Acid, a natural product, is reported to be antioxidative, is an effective inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the re...

Cgp 20309
(CAS: 122378-48-7)

Cgp 20309 has a thiocarbonylamides structure and it is a potent antifilarial agent under laboratory research stage.

pGlu-Pro-Arg-MNA
(CAS: 130835-45-9)

pGlu-Pro-Arg-MNA is a peptide compound that has potential biology activity in many areas.

CAS 34367-04-9 Ginsenoside Ro

Ginsenoside Ro
(CAS: 34367-04-9)

Ginsenoside Ro, the predominant ginsenoside in the rhizome, shows no hemolytic nor cytotoxic activities.

CCR1 antagonist
(CAS: 1003566-93-5)

CCR1 antagonist is a chemokine CCR1 antagonist. It is used for the treatment of chronic obstructive pulmonary disease.

MRT-92
(CAS: 1428315-82-5)

SBC-115076
(CAS: 489415-96-5)

SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist. .

CAS 553-12-8 Protoporphyrin IX

Protoporphyrin IX
(CAS: 553-12-8)

Created by the enzyme protoporphyrinogen oxidase, protoporphyrin IX is an important precursor to biologically essential prosthetic groups.

CVT10216
(CAS: 1005334-57-5)

CVT10216 is a potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) with IC50 value of 29nM, thereby inhibiting dopamine synthesis. It ...

CAS 949021-68-5 Sodium formononetin-3(acute)-sulfonate

Sodium formononetin-3(acute)-sulfonate
(CAS: 949021-68-5)

Sodium formononetin-3'-sulfonate is a water-sol. derivate of formononetin. It has a protective potential against myocardial infarction injury. It not only had f...

CAS 261365-11-1 MB05032

MB05032
(CAS: 261365-11-1)

MB05032 inhibits human liver FBPase with a potency (IC50 = 16 ± 1.5 nM) significantly greater than the natural inhibitor, AMP (IC50 = 1 μM), and the most well c...

CAS 472-61-7 Astaxanthin

Astaxanthin
(CAS: 472-61-7)

Carotenoid pigment found mostly in animal organisms, but also occuring in plants; thought to be the precursor of astacin. Astaxanthin is a carotenoid pigment fo...

CAS 107-43-7 Betaine

Betaine
(CAS: 107-43-7)

Betaine is used to treat homocystinuria.

LY 135114
(CAS: 126254-82-8)

LY 135114 is a metabolite of LY 195448. LY195448 is a Alpha adrenergic receptor originate by Eli Lilly. But clinical trials for the treatment of cancer had been...

CAS 75887-54-6 Arteether

Arteether
(CAS: 75887-54-6)

Artemotil is a fast acting blood schizonticide. It is a semi-synthetic derivative of artemisinin, which is a natural product of the Chinese plant Artemisia annu...

PKR-IN-2
(CAS: 1628428-01-2)

PKR-IN-2 is a pyruvate kinase (PKR) activator. IC50: PKR (R510Q) <100 nM

CAS 71610-00-9 Cephalomannine

Cephalomannine
(CAS: 71610-00-9)

Cephalomannine is an active anti-cancer agent obtained from Taxus yunnanensis and has an antineoplastic effect on tumors found in mice.

Reference Reading


1.Resolution of enantiomeric amides on a Pirkle-type chiral stationary phase. A comparison of subcritical fluid and liquid chromatographic approaches.
Macaudiere P, Tambute A, Caude M, Rosset R, Alembik MA, Wainer IW. J Chromatogr. 1986 Dec 26;371:177-93.
Subcritical and supercritical fluid chromatography (SubFC and SFC) have been evaluated for the resolution of an homologous series of enantiomeric amides. The solutes were the 2-naphthoyl amides of an homologous series of amines, ranging from 2-aminobutane to 2-aminoctane, and the p-methyl-, p-methoxy- and p-chlorophenylamides of 2-aminoheptane. The chiral stationary phase (CSP) used was the covalent form of (R)-N-(3,5-dinitrobenzoyl)phenylglycine. In liquid chromatography (LC) the mobile phase comprised hexane-2-propanol--acetonitrile (97:3:0.5) at a flow-rate of 2 ml/min and temperatures of 20-35 degrees C. In SFC, the mobile were various mixtures of carbon dioxide and polar modifiers, such as alcohols, chloroform and water. For the best conditions in LC, the chiral resolution, alpha, increased through the homologous series from alpha = 1.03 for the amide derived from 2-aminobutane to alpha = 1.11 for the 2-aminooctane amide. The values of alpha observed for the pi-basic amides of 2-aminoheptane (p-methyl and p-methoxy) were greater than that observed for the pi-acidic amide (p-chloro), i.
2.Biogenic amine-ionophore interactions: Structure and dynamics of lasalocid (X537A) complexes with phenethylamines and catecholamines in nonpolar solution.
Shen C1, Patel DJ. Proc Natl Acad Sci U S A. 1977 Nov;74(11):4734-8.
The ionophore lasalocid A forms 1:1 complexes with phenethylamines (1-amino-1-phenylethane and 1-amino-2-phenylethane) and catecholamines (dopamine and norepinephrine) in nonpolar solution. We have undertaken high-resolution proton nuclear magnetic resonance studies to deduce structural and kinetic information on the ionophore-biogenic amine complexes in chloroform solution. The coupling constant, chemical shift, and relaxation time data demonstrate that the lasalocid backbone conformation and the primary amine binding sites in the complexes are similar to those determined earlier for the alkali and alkaline earth complexes of this ionophore in solution. The exchange of lasalocid between the free acid (HX) and the primary amine complexes (RNH(3)X) in chloroform solution have been evaluated from the temperature-dependent line shapes at superconducting fields. The kinetic parameters associated with the unimolecular dissociation [Formula: see text] and the bimolecular exchange [Formula: see text] reactions have been deduced from an analysis of the lifetime of the complex as a function of the reactant concentrations.
3.Screening and confirmation capabilities of liquid chromatography-time-of-flight mass spectrometry for the determination of 200 multiclass sport drugs in urine.
Domínguez-Romero JC1, García-Reyes JF1, Lara-Ortega FJ1, Molina-Díaz A2. Talanta. 2015 Mar;134:74-88. doi: 10.1016/j.talanta.2014.10.050. Epub 2014 Oct 31.
In this article, a screening method for the determination of 200 sport drugs in human urine has been developed using liquid-chromatography electrospray time-of-flight mass spectrometry (LC-TOFMS). The chromatographic separation of the targeted doping agents was carried out by fast liquid chromatography using a C18 column (4.6×50 mm) with 1.8 μm particle size. Accurate mass measurements of the selected ion (typically [M+H](+) and [M-H](-)) along with retention time matching was used for the screening and detection of the targeted species. The proposed methodology comprised also a simple sample treatment stage based on solid-phase extraction (SPE) with polymeric cartridges. The SPE method displayed satisfactory recoveries rates (between 70 and 120%) for the majority of the compounds at both concentration levels tested (2.5 and 25 μg L(-1)). The overall performance of the method was satisfactory with all 200 compounds fulfilling WADA minimum required performance levels (MRPLs), with limits of quantitation lower than 1 μg L(-1) for 80% of the compounds, and showing an appropriate linearity (r(2)>0.